No actionable trading opportunity remains — APGE shares have been delisted and the merger with AbbVie is complete. Monitor for any residual distributions or tax-related filings from the merger consideration.
Price Chart
Executive Summary
Apogee Therapeutics has filed a Form 15-12G to terminate its SEC registration and suspend reporting obligations, effective September 14, 2026. This is the final step in the company's exit from public markets following its completed acquisition by AbbVie for approximately $10.9 billion, as confirmed by the prior 25-NSE delisting filing. With only 1 holder of record, the deregistration is a routine procedural step post-merger, not a standalone going-dark event.
Key Facts
- Apogee Therapeutics filed Form 15-12G to terminate registration under Section 12(g) of the Securities Exchange Act of 1934.
- The filing cites Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i) to suspend reporting duties.
- Approximate number of holders of record as of the certification date: 1.
- The company's principal executive offices are now c/o AbbVie, Inc. in North Chicago, Illinois.
- The filing follows a prior 25-NSE (filed September 3, 2026) confirming Nasdaq delisting after the completed AbbVie merger.
Financial Impact
No financial impact — deregistration is a procedural step following the completed $10.9B all-cash merger with AbbVie, where shareholders received $135.11 per share.
Risk Factors
- No residual public trading risk — the security is deregistered and delisted.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 15-12G Filing (Primary) | 0001140361-26-036410 |
| Document: 0001140361-26-036410-index-headers.html | 0001140361-26-036410 |
| Document: 0001140361-26-036410-index.html | 0001140361-26-036410 |
| Document: 0001140361-26-036410.txt | 0001140361-26-036410 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access